Suppr超能文献

III/IV级胶质瘤等待放射治疗的影响。

The effect of waiting for radiotherapy for grade III/IV gliomas.

作者信息

Do V, Gebski V, Barton M B

机构信息

Division of Radiation Oncology, Westmead Hospital, Westmead, NSW 2145, Australia.

出版信息

Radiother Oncol. 2000 Nov;57(2):131-6. doi: 10.1016/s0167-8140(00)00257-7.

Abstract

AIM

To determine the effect of waiting time for radiotherapy on the overall survival of patients with high-grade gliomas.

METHODS

We examined records of patients with grade III/IV gliomas who were referred to radiotherapy after surgery or biopsy - ECOG <3, any age, radical intent or palliative intent with dose >50 Gy, no interstitial or radiosurgery boost. Waiting time was defined in two ways, time from biopsy to radiotherapy and time from presentation to radiotherapy department to start of radiotherapy.

RESULTS

There were 182 patients in the study having a median survival of 8.5 months, with a median follow up of 10.5 months. The group comprised of 63 (35%) grade III and 119 (65%) grade IV gliomas. Median times and ranges from biopsy and presentation to treatment were 26 days (4-78 days) and 15 days (1-62 days), respectively. The median dose was 60 Gy in a median of 30 fractions over a median of 46 days. Tumour progression before and during radiotherapy occurred in seven patients (4%) and 19 patients (11%), respectively. One hundred and seventy-nine patients died of disease. The seven patients whose tumour progressed before radiotherapy were excluded from the analysis of prognostic variables. In a multivariate analysis the variables that were significantly associated with worse survival were older age, reduced dose and prolonged waiting time from presentation. The risk of death increased by 2% for each day of waiting for radiotherapy.

CONCLUSION

The study showed longer waiting time from presentation at radiotherapy department to treatment to be a significant predictor of overall survival for patients with high-grade glioma.

摘要

目的

确定放射治疗等待时间对高级别胶质瘤患者总生存期的影响。

方法

我们检查了III/IV级胶质瘤患者的记录,这些患者在手术或活检后接受放射治疗——东部肿瘤协作组(ECOG)评分<3,任何年龄,根治性或姑息性治疗意图,剂量>50 Gy,无间质或立体定向放射外科增强治疗。等待时间有两种定义方式,从活检到放疗的时间以及从就诊于放疗科到开始放疗的时间。

结果

本研究中有182例患者,中位生存期为8.5个月,中位随访时间为10.5个月。该组包括63例(35%)III级和119例(65%)IV级胶质瘤。从活检和就诊到治疗的中位时间及范围分别为26天(4 - 78天)和15天(1 - 62天)。中位剂量为60 Gy,中位分30次给予,中位疗程为46天。放疗前和放疗期间分别有7例患者(4%)和19例患者(11%)出现肿瘤进展。179例患者死于疾病。放疗前肿瘤进展的7例患者被排除在预后变量分析之外。在多变量分析中,与较差生存期显著相关的变量是年龄较大、剂量降低以及从就诊开始的等待时间延长。放疗等待的每一天死亡风险增加2%。

结论

该研究表明,从就诊于放疗科到开始治疗的等待时间延长是高级别胶质瘤患者总生存期的一个重要预测因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验